An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intravenous Pump-Delivered Propranolol in Patients With ICH

Inclusion Criteria: * Patients aged \> 18 and ≤ 80 years of age; * Can be treated with the study drug within 24 h of symptom onset; * No fever or infection was observed upon admission; * NIHSS score ≥10; * Supratentorial parenchymal haematoma (≥10 mL); * GCS score ≥ 6; * Patients or their family members sign informed consent forms. Exclusion Criteria: * Infections within the last 4 weeks; * Use of antibiotics within the last 2 weeks; * Known pre-ICH dysphagia; * Secondary intracerebral hemorrhage or intraventricular hemorrhage resulting from trauma, vascular malformation, aneurysm, coagulopathy, anticoagulant drugs, thrombolysis, post-infarction hemorrhage transformation, hematopathy, moyamoya disease, primary or metastatic tumor, venous sinus thrombosis, vasculitis, and other definite causes; * Previous disability with pre-ICH mRS score ≥ 2; * Brainstem hemorrhage; * Life expectancy less than 14 days; * Death appeared imminent; * Pregnancy or within 30 d of delivery; * Previous use (within 1 month) of β-blockers or reserpine; * Bronchial asthma or COPD; * Cardiogenic shock; * Degree II-III atrioventricular blocks; * Severe or acute heart failure; * Heart rate \< 65 beats/min; * Known to be allergic to propranolol; * Severe liver or renal insufficiency; * History of malignant tumors; * Currently participating in other interventional clinical trials; * Currently, immunosuppressants and immunotherapies are being administered.